AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 182 min read$ABT

Abbott to pay $385 million over Michigan baby formula recall that fueled 2022 shortage

Abbott Laboratories agreed to a $385 million settlement over its 2022 recall of baby formula from its Michigan plant, which exacerbated a nationwide shortage. The settlement resolves claims from the DOJ, relators, and state attorneys general. Abbott denies fault or liability. The plant was closed due to contamination concerns but reopened by June 2022. The Biden administration took emergency measures to address the shortage.

Original reporting
finance.yahoo.com
Published Sep 18, 2026, 1:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 3:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott to pay $385 million over Michigan baby formula recall that fueled 2022 shortage — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The settlement caps legal exposure but does not admit liability, likely stabilizing Abbott's stock.

02

Market read

Resolution of a high‑profile legal case removes a lingering risk factor for Abbott, offering a modest trading catalyst.

03

What to watch

Potential future regulatory scrutiny on infant‑formula safety standards could impact Abbott long‑term.

Relevance 8/10Novelty 8/10Timing: announcement today

Background

Abbott's Sturgis plant was the largest U.S. baby‑formula facility; its 2022 shutdown triggered a nationwide shortage.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott Laboratories announced a $385 million settlement to resolve claims from the 2022 Michigan baby‑formula plant shutdown.

Expected impact

Modest short‑term upside as investors view the resolution as a closure of a lingering risk.

Evidence & confidence

The amount is material and the news is new; markets typically react positively to the removal of legal uncertainty.

Market effects

Sector

Consumer health and nutrition sector may see reduced litigation risk perception.

Regional

Michigan‑based suppliers could experience slight relief in supply‑chain concerns.

Global

Limited; the settlement is US‑focused and does not affect global formula markets.

Counterpoint

What could challenge this read

Some investors may view the settlement as a sign of deeper product‑safety issues that could resurface.

Key entities

  • Company
    Abbott Laboratories

    US‑listed health‑care company (ticker ABT).

  • Government Agency
    U.S. Department of Justice

    Federal agency involved in the investigation and settlement.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 17
$ABTMedAI 8/10

Attorney General James Secures Over $9 Million for New York from Abbott Laboratories for Manufacturing Potentially Unsafe Baby Formula

New York Attorney General Letitia James announced a settlement with Abbott Laboratories, where the company will pay over $384 million for alleged safety violations in its baby formula products. Abbott is accused of failing to maintain safety standards from 2018 to 2022, leading to potential contamination and misuse of Medicaid and WIC funds. New York will receive over $9.3 million from the settlement.

longisland.com2 min
SEP 17
$ABTMedAI 8/10

Abbott Must Pay $384M for 2022 Contaminated Baby Formula: Who Gets the Payout

Abbott Laboratories agreed to pay $385M to settle allegations of selling contaminated infant formula to government programs, contributing to the 2022 formula crisis. The settlement resolves False Claims Act allegations but does not establish a consumer claims process. The Justice Department emphasized the importance of adhering to health and safety standards for infant formula.

newsweek.com6 min
SEP 17
$ABTHighAI 9/10

Abbott Laboratories agrees to pay more than $384 million to settle infant formula allegations

Abbott Laboratories agreed to pay over $384 million to settle allegations of submitting false claims for infant formula and nutritional products. The settlement includes $348.7 million to the federal government and $35.5 million to states, resolving claims involving products made between 2018 and 2022 at facilities in Michigan and Arizona. Authorities alleged Abbott failed to meet safety and regulatory requirements, leading to potential contamination risks. The settlement does not admit liabilit

wrnjradio.com2 min